Week in Review: Three New/Expanded Collaborations in Holiday-Shortened Week

Deals and Financings

• Fosun Pharma’s Wanbang subsidiary added animal rights to its development agreement with Vancouver’s Sirona Biochem for a SGLT2 diabetes 2 therapy;
• Nona Biosciences, a Harbour BioMed subsidiary, will collaborate with Boston-area Dragonfly to discover candidates for bispecific/multi-specific antibodies;
• Shanghai IASO Bio will collaborate with Umoja Biopharma of Seattle to test the efficacy of Umoja's iCIL off-the-shelf cell therapy platform with IASO’s CAR candidates;

Trials and Approvals

• Yantai Luye Pharma’s extended-release therapy for schizophrenia and schizoaffective disorders met its endpoints in a US pivotal trial;
• AnchorDx, a Guangzhou company focused on early detection of cancers, enrolled the first patient in a US trial of its UriFind® bladder cancer assay;
• Nanjing Triastek was cleared to start US trials of T21, a 3D printed medicine with a targeted release mechanism, for ulcerative colitis.

Stock Symbols: (TSX-V: SBM) (HK: 02142) (HK: 2186)

Share this with colleagues: